Patents by Inventor Xin Duan

Xin Duan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phosphoramidate Alkylator Prodrugs
    Publication number: 20110251159
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: June 17, 2011
    Publication date: October 13, 2011
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao, Jacob Kaizerman
  • Phosphoramidate alkylator prodrugs
    Patent number: 8003625
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: August 23, 2011
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao, Jacob Kaizerman
  • PHOSPHORAMIDATE ALKYLATOR PRODRUGS FOR THE TREATMENT OF CANCER
    Publication number: 20100183742
    Abstract: Compositions containing, and, methods administering, TH302, are useful in treatment of cancer and other hyper-proliferative diseases.
    Type: Application
    Filed: December 21, 2007
    Publication date: July 22, 2010
    Applicant: Threshold Pharmaceuticals, Inc
    Inventors: Steve Ammons, Jian-Xin Duan, Donald Jung, Mark Matteucci
  • PHOSPHORAMIDATE ALKYLATOR PRODRUGS
    Publication number: 20100137254
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered along or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: June 29, 2006
    Publication date: June 3, 2010
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao
  • GLUFOSFAMIDE COMBINATION THERAPY
    Publication number: 20100104549
    Abstract: The co-administration of glufosfamide and a glucose lowering drug other than insulin is efficacious in cancer treatment.
    Type: Application
    Filed: April 7, 2008
    Publication date: April 29, 2010
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Damian Handisides, Stewart Kroll, Jian-Xin Duan, Harold E. Selick
  • Compositions and Methods for Treating Cancer
    Publication number: 20090312276
    Abstract: Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: June 12, 2009
    Publication date: December 17, 2009
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • Compositions and methods for treating cancer
    Patent number: 7550496
    Abstract: Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: March 29, 2004
    Date of Patent: June 23, 2009
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • Tubulin Binding Anti Cancer Agents And Prodrugs Thereof
    Publication number: 20090042820
    Abstract: Novel tubulin binding compounds and hypoxia activated prodrugs of novel and known tubulin binding compounds useful for treating cancer and other hyperproliferative diseases are disclosed.
    Type: Application
    Filed: November 17, 2005
    Publication date: February 12, 2009
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Xiaohong Cai
  • Topoisomerase Inhibitors and Prodrugs
    Publication number: 20080214576
    Abstract: Compositions and methods for treating cancer and other hyperproliferatice disease conditions with topoisomerase inhibitors and their prodrugs are disclosed.
    Type: Application
    Filed: November 27, 2005
    Publication date: September 4, 2008
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Photon Rao
  • Hypoxia-Activated Anti-Cancer Agents
    Publication number: 20080132458
    Abstract: Prodrugs of cyclic anthracyclin toxins comprising a hypoxia-activated trigger and are disclosed. In addition, methods of treating cancer using the compounds of the invention are disclosed.
    Type: Application
    Filed: March 10, 2005
    Publication date: June 5, 2008
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan
  • Anthracycline analogs
    Publication number: 20070060534
    Abstract: Anthracycline analogs and their bioconjugates are useful as anticancer agents.
    Type: Application
    Filed: June 30, 2006
    Publication date: March 15, 2007
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Xiaohong Cai
  • Lonidamine analogs
    Publication number: 20070043057
    Abstract: Lonidamine analogs are useful in the treatment and prevention of cancer, benign prostatic hyperplasia, macular degeneration and prostatic intraepithelial neoplasia, or for use as an antispermatigenic agent.
    Type: Application
    Filed: February 1, 2006
    Publication date: February 22, 2007
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • Lonidamine analogs
    Publication number: 20070015771
    Abstract: Lonidamine analogs are useful in the treatment and prevention of cancer, benign prostatic hyperplasia, macular degeneration and prostatic intraepithelial neoplasia, or for use as an antispermatigenic agent.
    Type: Application
    Filed: February 8, 2006
    Publication date: January 18, 2007
    Applicant: Threshold pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • Compositions and methods for treating cancer
    Publication number: 20060258656
    Abstract: Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: March 29, 2004
    Publication date: November 16, 2006
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • Process for the preparation of derivatives of octafluoro-[2,2] paracylophane
    Patent number: 6392097
    Abstract: Processes for the preparation of parylene dimers, and more particularly to processes for the preparation of derivatives of octafluoro-[2,2]paracylophane, otherwise known as AF4.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: May 21, 2002
    Assignee: Specialty Coating Systems, Inc.
    Inventors: William R. Dolbier, Jr., Jian-Xin Duan, Alex J. Roche
  • Process for the preparation of derivatives of octafluoro-[2,2]paracylophane
    Publication number: 20020026086
    Abstract: Processes for the preparation of parylene dimers, and more particularly to processes for the preparation of derivatives of octafluoro-[2,2] paracylophane, otherwise known as AF4.
    Type: Application
    Filed: March 20, 2001
    Publication date: February 28, 2002
    Inventors: William R. Dolbier, Jian-Xin Duan, Alex J. Roche
  • Parylene AF4 synthesis
    Patent number: 5841005
    Abstract: Methods of making parylene AF4 using novel that result in reduced cost. Low dilution technology may used to provide parylene AF4 in substantially improved yields. The relative amount of transition metal catalyst can be decreased. The amount of undesired byproduct is also reduced.
    Type: Grant
    Filed: March 14, 1997
    Date of Patent: November 24, 1998
    Inventors: William R. Dolbier, Jr., Jian-Xin Duan, Alex J. Roche